Dr Zhang from John Hopkins University just published an important article in PLoS One on innovative drug combinations for the treatment of Lyme disease.
Dr Zhang from John Hopkins University just published an important article in PLoS One on innovative drug combinations for the treatment of Lyme disease.
"Of studied drugs, daptomycin was the common element in the most active regimens when combined with doxycycline plus either beta-lactams (cefoperazone or carbenicillin) or an energy inhibitor (clofazimine). Daptomycin plus doxycycline and cefoperazone eradicated the most resistant microcolony form of B. burgdorferi persisters and did not yield viable spirochetes upon subculturing, suggesting durable killing that was not achieved by any other two or three drug combinations. These findings may have implications for improved treatment of Lyme disease, if persistent organisms or detritus are responsible for symptoms that do not resolve with conventional therapy. Further studies are needed to validate whether such combination antimicrobial approaches are useful in animal models and human infection". Research monies and grants are now needed ASAP to test out these drug combinations in clinical practice in order to relieve the suffering of those with Lyme-MSIDS.
http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0117207
http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0117207
Although most Lyme disease patients can be cured with antibiotics doxycycline or amoxicillin using 2-4...
JOURNALS.PLOS.ORG
